The vaccine is currently undergoing clinical trials for children aged 8 to 32 weeks. Studies for older age groups have already been completed. After completing all the necessary tests, scientists plan to submit the documents to the Russian Ministry of Health at the end of 2025.
Previously, the Russian Ministry of Health had given permission to the Federal Medical and Biological Agency (FMBA) to conduct phase III clinical trials of the Allergarda vaccine. The drug is intended for the prevention of allergies to birch pollen and related cross-food reactions. Before this stage, preclinical trials and the first stages of clinical trials of the vaccine were carried out.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
